FDAnews Drug Daily Bulletin

VIREXX FILES CTA FOR HEPAPTITIS B THERAPEUTIC VACCINE

Dec. 9, 2005
A A

ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, announced today that it has filed a Clinical Trial Application with Health Canada for a Phase I trial of HepaVaxx B, an important proof of principle for the ChimigenTM platform. HepaVaxx B is being developed as a therapeutic vaccine for the treatment of patients chronically infected with hepatitis B.

CCNMatthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=571193)